For the first time we could identify CD1A as a potential biomarker, whose reduced expression both on tumor and on tumor-infiltrating immune cells is associated with an early relapse after R0 resection of lung adenocarcinomas. The gene discussed is CD1A; the disease is lung adenocarcinoma.